11 July 2024
Incanthera
plc
("Incanthera" the
"Company")
Commercial Order
Update
Second Production Order
Confirmed
Incanthera plc (AQSE:INC), the
company specially focused on innovative technologies in dermatology
and oncology, is pleased to announce that the second production
order for 250,000 units has been confirmed as the next step in our
commercial deal with Marionnaud AG, part of the Watsons
Group.
On 3 June 2024, in a Commercial
Update to the market, Incanthera advised that, following meetings
in Switzerland with Marionnaud and A.S. Watson, our
first production order ("Launch Order") for
Incanthera's luxury skincare brand
range, Skin + CELL, had risen from 50,000
units to 100,000 units in anticipation of higher demand, yielding
expected Increased first order revenues of c. £4 million.
It was also indicated that the
second production order would be larger, at an estimated 250,000
units, to fulfil the European launch demand.
As a result of continuing
discussions with Marionnaud and A.S.
Watson, the Company is pleased to confirm
that the second production order for 250,000 has now been placed by
Skin and Cell AG to Frike Cosmetic A.G. in
Switzerland for supply to Marionnaud to meet the anticipated demand
for further European roll out and the start
of the planned Asian roll out.
The second production
order, scheduled for delivery in the
current financial year (ending 31 March 2025), brings
total placed orders to over 350,000 units of its products
with Frike Cosmetics in Switzerland for supply to Marionnaud and
other members of the AS Watson Group, supporting management's projected revenues for this year to
exceed £10 million and for Incanthera to achieve
profitability
Incanthera's Launch Order of 100,000
units is currently in production with our manufacturing licensing
supplier, Frike Cosmetic A.G. for delivery to Marionnaud in
preparation for launch in September.
Incanthera's manufacturing deal with
Frike Cosmetic A.G., as announced in conjunction with the
commercial deal in December 2023, ensures they hold responsibility
for the full manufactured product of Skin + CELL, which includes
bottles, receipt of raw materials, i.e. formulation to fill
bottles, packaging and printing of our final Skin + CELL branded
product.
This is overseen by Incanthera's
Swiss subsidiary, Skin + CELL A.G., responsible for the worldwide
distribution of Skin + CELL's range of five luxury skincare
products (Face, Hand, Body, Serum and Eye Cream) which is to be
launched in September 2024, through c. 60 of Marionnaud's highest
traffic stores, in Switzerland and Austria.
Skin + CELL A.G. is also currently
focused on preparation of pre-launch in-store education and
pre-marketing schedules, demonstrating the essential infrastructure
and manufacturing operational synergies with Marionnaud as the
teams work together.
The Company is delighted in the
ongoing commitment and enthusiasm of Marionnaud for
Skin + CELL's unique science-based skincare
and their demonstrable confidence of the
anticipated demand for our Skin + CELL range to their European
customer base and the wider A.S. Watson Group.
Incanthera retains the right to
commercial discussions for potential licensing deals with other
organisations in all other global territories outside those in
which Marionnaud and AS Watson will have geographical exclusivity
to Skin + CELL.
Commenting, Chairman, Tim McCarthy,
said:
"It is fantastic to bring this further
positive update to the market.
This clearly evidences the confidence and anticipation with
which Incanthera, and its Swiss subsidiary, Skin + CELL A.G. is
managing the production order cycle, in close coordination with
Marionnaud, as the teams work collaboratively towards the launch
and roll out of Skin + CELL in Europe.
The essential infrastructure and framework that the team
established for the Commercial deal announcement in December 2023
is now in full operation as we ramp up the production orders and
prepare for launch.
The resulting revenues generated to Incanthera will allow us
to further bolster our inventory capacity and ongoing commercial
operational model, thereby driving revenue growth and, in turn,
increasing the value of our company and the capacity for returns to
shareholders."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
The Directors of Incanthera accept
responsibility for this announcement.
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury
skincare brand utilising our ground-breaking formulation and
delivery expertise, to bring scientifically proven formulations to
cosmetics. Skin + CELL's unique formulations, enriched with
targeted bioactive B3 (an activated form of niacinamide) are
delivered directly into the skin's cells to optimise and protect
cellular health, energy and protective capabilities.
Incanthera's skincare technology
harnesses unique delivery pathways through recently patented
formulations designed by our in-house experts who have previously
formulated skincare for some of the world's leading skincare and
pharmaceutical companies. These formulations fortify otherwise
depleted physiological pathways to improve the skin's performance,
ability to self-repair and to address previously unmet cosmetic
conditions in skin health.
•
Skin + CELL's unique formulations, currently
enriched with targeted bioactive B3 (an activated form of
niacinamide) but anticipating further bioactive ingredient
formulations are delivered directly into the skin's cells to
optimise cellular health, energy and protective
capabilities.
•
Independent studies have shown Incanthera's
technology is uniquely effective in delivering Bioactive B3 into
the skin, energising the living cells of the skin to maintain
natural health and protection against adverse environmental
challenges and maintaining even skin tones.
•
Skin + CELL's complementary range of products are
based on advanced, clinically designed, formulation concentrates
which combine leading edge pharmaceutical enhancement technology
with selected prestige cosmetic ingredients to give an effective
product which gives a silky emollience in use and leaves the skin
visibly radiant, energised and protected.
Skin + CELL's luxury skincare
current range extends across face, body, hand, face serum and eye
cream, and will also include SPF concentrations and further
bioactive derivatives of vitamins in the future.
About Marionnaud
Marionnaud is the largest luxury
perfumery and cosmetics chain in Europe with over 1,220 stores and
a 27% market share in France. Marionnaud is managed by the AS
Watson Group based in Hong Kong, the world's largest international
health and beauty retailer.
https://www.marionnaud.com
About A.S. Watson
The A.S. Watson Group is the
world's largest international health and beauty retailer, with
16,100 stores in 28 markets, primarily in Asia and Europe. A
member of CK Hutchison Holdings, A.S. Watson operates the world's
largest portfolio of retail formats, retail brands and has the
largest geographical presence including a significant online retail
presence.
http://www.aswatson.com/
https://youtu.be/IZ6TolZi4Go
Forward looking statement disclaimer
Certain statements made in this
announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the
Company's current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions shareholders
and prospective shareholder holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.